• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparison of Serum Selenium Levels Between Patients with Newly Diagnosed Atrial Fibrillation and Normal Controls
Biol Trace Elem Res. 2022 May 9. doi: 10.1007/s12011-022-03281-9. Online ahead of print.ABSTRACTAtrial fibrillation (AF) is the most common sustained dysrhythmia in the elderly population. It is estimated to affect more than 30 million people worldwide. AF occurs when abnormal electrical impulses start to activate in the atria and override the heart's natural pacemaker, which can no longer control the heart's rhythm. Since atrial contractility is impaired in AF, blood flow in the atria becomes stasis over time and causes thrombus formation. This thrombus causes the risk of embolism and causes complications such as stroke. ...
Source: Biological Trace Element Research - May 8, 2022 Category: Biology Authors: Isa Ardahanli Halil Ibrahim Ozkan Source Type: research

Predictors of Postoperative Atrial Fibrillation after Coronary Artery Bypass Grafting: A Prospective Cohort Study
ConclusionThere are a wide range of significant epidemiological, clinical, and operative predictors for the development of post-CABG AF including older age, female gender, large LA diameter, higher CHA2DS2-VASc score, valve replacement and postoperative inotropic support. Nevertheless, further large-scale studies are still needed to confirm our findings.
Source: QJM - October 1, 2021 Category: Internal Medicine Source Type: research

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Urinary potassium excretion and risk of cardiovascular events Cardiovascular disease risk
Conclusion: In this cohort with oversampling of subjects with albuminuria at baseline, urinary potassium excretion was not independently associated with a lower risk of cardiovascular events.
Source: American Journal of Clinical Nutrition - May 1, 2016 Category: Nutrition Authors: Kieneker, L. M., Gansevoort, R. T., de Boer, R. A., Brouwers, F. P., Feskens, E. J., Geleijnse, J. M., Navis, G., Bakker, S. J., Joosten, M. M., for The PREVEND Study Group Tags: Cardiovascular disease risk Source Type: research

Urinary potassium excretion and risk of cardiovascular events.
CONCLUSION: In this cohort with oversampling of subjects with albuminuria at baseline, urinary potassium excretion was not independently associated with a lower risk of cardiovascular events. PMID: 26984482 [PubMed - as supplied by publisher]
Source: The American Journal of Clinical Nutrition - March 16, 2016 Category: Nutrition Authors: Kieneker LM, Gansevoort RT, de Boer RA, Brouwers FP, Feskens EJ, Geleijnse JM, Navis G, Bakker SJ, Joosten MM, PREVEND Study Group Tags: Am J Clin Nutr Source Type: research